SCHEMBL6609503

SCHEMBL6609503

COC(=O)C(CO)N(Cc1ccccc1NC(=O)C(F)(F)F)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 6/20 0.52
KEAP1 Q14145 4/20 0.51
NFE2L2 Q16236 1/20 0.51
KDM4E B2RXH2 1/20 0.48
MMP8 P22894 6/20 0.46
MMP13 P45452 6/20 0.46
MMP1 P03956 2/20 0.46
MMP7 P09237 1/20 0.46
MMP12 P39900 1/20 0.46
MMP2 P08253 5/20 0.45
MMP9 P14780 5/20 0.45
POLB P06746 1/20 0.42
GRK2 P25098 1/20 0.42
PPARG P37231 1/20 0.42
KMT2A Q03164 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
NR2E3 Q9Y5X4 1/20 0.42
NCOR2 Q9Y618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6613444 0.85 KEAP1 (0.53) BMP1KEAP1NFE2L2MMP8MMP13
SCHEMBL5655796 0.82 KEAP1 (0.56) BMP1KEAP1NFE2L2MMP8MMP13
SCHEMBL6610195 0.82 BMP1 (0.47) BMP1KEAP1NFE2L2MMP13MMP1
SCHEMBL5654237 0.80 MMP1 (0.69) KEAP1NFE2L2MMP8MMP13MMP1
SCHEMBL6611811 0.78 KDM4E (0.48) BMP1KEAP1NFE2L2KDM4EMMP8
SCHEMBL6610164 0.75 BMP1 (0.48) BMP1KEAP1NFE2L2MMP8MMP13
SCHEMBL8023076 0.74 KEAP1 (0.46) BMP1KEAP1NFE2L2MMP8MMP13
SCHEMBL6616241 0.74 MMP1 (0.54) BMP1KEAP1NFE2L2MMP8MMP13
SCHEMBL6611787 0.73 KEAP1 (0.46) BMP1KEAP1NFE2L2MMP8MMP13
SCHEMBL6611785 0.73 KEAP1 (0.46) BMP1KEAP1NFE2L2MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147095-B1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH CORP (US) 2004-08-11 EP disclosed
US-6544984-B1 Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. AMERICAN CYANAMID COMPANY 2003-04-08 US disclosed
EP-1147095-A1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2001-10-24 EP disclosed
EP-1051407-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2000-11-15 EP disclosed
WO-2000044730-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed
WO-1999037625-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-07-29 WO disclosed